RxDoctor Payments DataLook up a doctor →

Imran Sheriff, MD

Family Medicine · Reno, NVNPI 1659373678

Payments from drug & device makers

$10,292in general payments, 2019–2025

Across 508 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • AbbVie$1K
  • Astellas Pharma US Inc$913
  • Boehringer Ingelheim$660
  • Pfizer$535
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$9,68194%
  • Education$6126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,292 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$168,425
Medicare patients
271
Services billed
2,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide190$345,581
JardianceEmpagliflozin211$318,275
Trelegy ElliptaFluticasone/Umeclidin/Vilanter188$266,098
TradjentaLinagliptin183$232,761
EliquisApixaban144$191,985
FarxigaDapagliflozin Propanediol111$140,706
JanuviaSitagliptin Phosphate88$107,250
MounjaroTirzepatide56$82,962
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr64$68,418
CreonLipase/Protease/Amylase28$67,636
XareltoRivaroxaban52$65,891
GlyxambiEmpagliflozin/Linagliptin34$56,302
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$55,567
LinzessLinaclotide43$50,712
Breo ElliptaFluticasone/Vilanterol54$47,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat, Stiolto Respimat$660$650,837469 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,044$382,261306 claims
Novo NordiskOzempic$187$345,581190 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,898$206,764177 claims
PfizerEliquis$535$191,985144 claims
AbbVieCreon, Linzess$1,349$118,34771 claims
Lilly USA, LLCMounjaro, Trulicity$210$117,80674 claims
MerckJanuvia$24$107,25088 claims
Johnson & JohnsonXarelto$105$65,89152 claims
Astellas Pharma US IncMyrbetriq$913$45,33445 claims
BayerKerendia$495$37,41223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →